Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Eastern Cooperative Oncology Group
University of California, Irvine
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
City of Hope Medical Center
Thomas Jefferson University
University of Washington
National Cancer Institute (NCI)
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
City of Hope Medical Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Royal North Shore Hospital
Stanford University
Maastricht Radiation Oncology
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Vanderbilt-Ingram Cancer Center
Pinnacle Biologics Inc.
University of Wisconsin, Madison